2 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Withdrawn 2 |
| Phase 2 | 2 | Withdrawn 2 |
Follow Agendia: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LY3200882 and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer (EORTC1615) LY3200882 - Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Withdrawn | The Netherlands Cancer Institute | 2020-01-01 | 2025-09-05 | |
| Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer Galunisertib - Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Withdrawn | The Netherlands Cancer Institute | 2018-08-24 | 2019-07-24 |
Capecitabine (2) · LY-2157299 (1)
Netherlands (1)
A Bardelli, Prof (2) · A Cervantes, Prof (2) · J Tabernero, Prof (2) · R Bernards, Prof (2) · R Salazar, MD, PhD (2) · S Siena, Prof (2) · S Tejpar, Prof (2) · F Ciardello, Prof (1) · F Ciardiello, Prof (1)
2016 (1)